New User:

-or-
Username:
Password:
Forgot your password?
News Breaks
November 4, 2009
16:15 EDTSRDX
theflyonthewall.com: SurModics reports Q4 EPS 16c vs. consensus of 20c
Reports Q4 revenue $19.2M vs. consensus $19.28M. :theflyonthewall.com



News For SRDX From The Last 14 Days
Check below for free stories on SRDX the last two weeks.
There are 8 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
February 10, 2012
16:19 EDTSRDX
theflyonthewall.com: SurModics files Form 10-Q, delays annual report

Subscribe for More Information
:theflyonthewall.com

February 6, 2012
08:16 EDTSRDX
theflyonthewall.com: SurModics affirms FY12 view EPS 45c-53c vs. consensus 46c

Subscribe for More Information
:theflyonthewall.com
08:14 EDTSRDX
theflyonthewall.com: SurModics may have to restate Q4, FY statements
Gary Maharaj, President and CEO of SurModics, stated, "In the process of preparing our financial statements for the quarter ended December 31, 2011, management determined the need to reevaluate the application of GAAP related to our accounting treatment associated with the fourth quarter 2011 asset impairment charge and the subsequent sale of substantially all the assets of the Pharmaceuticals business. As a result, the Company may need to restate its financial statements for the fourth quarter and fiscal year ended September 30, 2011. While it is unfortunate that this reevaluation is causing a delay in the release of our financial results and earnings call, we stress the fact that any potential adjustments would be non-cash in nature related to the Pharmaceuticals business, and will not affect our results from continuing operations in the first quarter of 2012." :theflyonthewall.com
08:12 EDTSRDX
theflyonthewall.com: SurModics reports preliminary Q1 adjusted EPS 11c vs. consensus 11c
Sees Q1 revenue from continuing operations $11.9M vs. consensus $12.63M. Results for the first quarter were impacted by a $2.0M decline in royalty revenue associated with Cypher and Cypher Select Plus drug eluting stents. :theflyonthewall.com

February 3, 2012
14:02 EDTSRDX
theflyonthewall.com: SurModics downgraded to Hold from Buy at Feltl

Subscribe for More Information
:theflyonthewall.com
05:18 EDTSRDX
theflyonthewall.com: SurModics backs FY12 EPS 45c-53c vs. consensus 46c
Backs FY12 revenue $47M-$51M vs. consensus $50.26M :theflyonthewall.com
05:17 EDTSRDX
theflyonthewall.com: SurModics may have to restate Q4, FY statements

Subscribe for More Information
:theflyonthewall.com
05:14 EDTSRDX
theflyonthewall.com: SurModics reports Q1 EPS 16c vs. consensus 11c

Subscribe for More Information
:theflyonthewall.com